Nucleic Acid Degradation Pathways in Liver Transfection

ByAdmin

Delivering genes or siRNAs to the liver is only half the battle – once there, the nucleic acid must persist long enough to be effective. The body has evolved potent nuclease systems to degrade foreign genetic material as a defense against viruses and transposons. Therefore, nucleic acid degradation pathways represent a major hurdle in liver transfection, limiting the duration and level of transgene expression or gene silencing.

Key stages where degradation occurs include:

  • The bloodstream or interstitial fluids, where extracellular nucleases (like DNase I and RNases) can rapidly digest unprotected nucleic acids.
  • The endosomal-lysosomal pathway inside cells, which can break down nucleic acids that fail to escape into the cytosol after endocytosis.
  • The cytoplasm and nucleus, where enzymes can degrade nucleic acids that aren’t properly shielded or integrated.

Understanding these pathways informs the design of delivery vectors and chemical modifications to improve nucleic acid stability.

Extracellular and Bloodstream Degradation

When plasmid DNA is injected (e.g., via tail vein), it faces DNases in the blood. Studies in mice have shown that naked plasmid is cleared with a half-life of ~5–10 minutes. Kawabata et al. reported that >90% of a plasmid dose was degraded within a few minutes post-injection. This underscores why delivering naked DNA without a carrier typically results in negligible gene expression except in special cases like hydrodynamic injection (where a huge volume and pressure temporarily overwhelms clearance). Similarly, naked siRNAs or mRNAs in blood are very unstable, being quickly broken down by RNases ubiquitous in serum.

To combat this, delivery vehicles are used: cationic liposomes, polymer nanoparticles, or viral capsids protect nucleic acids from immediate nuclease attack by encapsulating or condensing them. Altogen’s liver in vivo transfection reagent is a biodegradable lipid nanoparticle that forms stable complexes with DNA/RNA. The product description states the complexes remain intact in serum for over 16 hours. This prolonged stability suggests that nucleases have difficulty accessing the DNA while it’s bound in the lipid particles. In practical terms, this allows the DNA to circulate and reach the liver intact rather than being destroyed in minutes. Another strategy is chemical modification: synthetic siRNAs are often chemically modified (phosphorothioate backbones, 2’ sugar modifications, etc.) to resist RNase degradation.

Endosomal and Lysosomal Degradation

After uptake by hepatocytes (often via endocytosis when using non-viral vectors), the cargo is in endosomes. If it stays sequestered, it will eventually traffic to lysosomes, where DNase II (also known as acid DNase) resides at an acidic pH. DNase II can digest DNA in lysosomes – a process normally important for disposing of DNA from apoptotic cells or viral DNA that has been endocytosed by immune cells. In transfection context, if a DNA polyplex doesn’t escape the endosome, much of the DNA can be degraded by DNase II. A study has identified DNase II as a “lysosomal barrier to transfection,” meaning transfection efficiency improved when DNase II was inhibited or absent. This highlights the importance of endosomal escape. PEI’s proton sponge effect is one way to get out; many lipids are also designed to fuse with endosomal membranes triggered by low pH, releasing DNA to the cytosol before lysosomal fusion.

Even after endosomal escape, foreign DNA in the cytosol is still not fully safe. The cytosol has exonucleases like TREX1, which is a 3’ to 5’ exonuclease that degrades single-stranded DNA and possibly double-stranded DNA fragments in the cytosol. TREX1 normally functions to prevent accumulation of cytosolic DNA that could trigger interferon responses (loss of TREX1 leads to autoimmunity due to cGAS-STING activation). For transfection, if plasmid DNA is partially degraded or linearized, TREX1 might nibble on it. Indeed, one study found that removing TREX1 increased the persistence of transgene expression, as the DNA wasn’t being degraded as quickly. Conversely, some highly effective DNA delivery methods, like certain viral vectors (AAV), deliver genomes that either quickly enter the nucleus or are structured (single-stranded but with self-complementary forms) such that they avoid cytosolic sensing and maybe degradation.

For RNA therapeutics in the cytosol (like siRNA or mRNA for protein expression), RNases in the cytosol can degrade them. The cell has various RNases (e.g., RNase A family in extracellular space, and RNase L can be activated by interferon pathways intracellularly). Modifications such as 5’ capping, pseudouridine substitution in mRNA, and incorporation of modified bases in siRNA all serve dual roles of reducing immunogenicity and increasing stability against nucleases. For instance, a fully unmodified mRNA gets degraded relatively fast in cells, whereas modified mRNA can be translated for much longer.

Nuclear Degradation and Epigenetic Silencing

If DNA reaches the nucleus without integrating, over time it may be subject to slow degradation or silencing. While there aren’t many free DNases in the nucleus (since genomic DNA is protected by chromatin), episomal plasmids might be targeted by nucleases during cell division or by base excision repair mechanisms. Some evidence suggests that over weeks, non-integrated plasmids in mouse liver gradually diminish (partly by dilution due to cell division, partly by nucleases).

Moreover, even without physical degradation, epigenetic silencing can “functionally degrade” the expression (as discussed in the epigenetics section). Methylation of CpGs on plasmid DNA doesn’t chop it up, but it effectively “degrades” its activity. Histone modifications can lock it down such that even though the plasmid persists, it’s transcriptionally inert. Using CpG-free plasmids avoids a trigger for such silencing and may prolong active life of the plasmid. Also, minicircle DNA, which lacks bacterial backbone, persists with expression longer likely because it doesn’t recruit as many repressors.

Strategies to Evade Degradation

Combining insights from above, effective liver transfection protocols incorporate multiple protective strategies:

  • Chemical modifications: As noted, siRNAs are often 2’-O-methyl modified at select bases and have phosphorothioate bonds on the ends to resist exonucleases. mRNA therapies (like the COVID-19 vaccines for example) use N1-methylpseudouridine instead of uridine to reduce RNase recognition and innate sensing.
  • Formulation: Packaging nucleic acids in nanoparticles (lipid nanoparticles, LNPs, being the leading method) largely solves the extracellular stability problem. LNPs used in patisiran (an FDA-approved siRNA for TTR amyloidosis) allow siRNA to circulate and then target the liver via apolipoprotein E-mediated uptake by hepatocytes. The success is evidenced by potent gene silencing for weeks: experiments showed single doses of such siRNA-LNPs silenced a gene (like PCSK9) in mouse liver for up to 3 weeks. This durability arises from both efficient uptake and the chemical stability provided by the formulation and modifications (the siRNA in that case likely had stabilizing modifications too).
  • Dosage and re-dosing: In some cases, these pathways cannot be fully circumvented, so the practical approach is to account for them. For short-term experiments, one might saturate nucleases by using a high dose (e.g., hydrodynamic injection uses a huge bolus of DNA – some gets degraded but a lot enters hepatocytes quickly). In therapeutic contexts, repeat dosing of a gene therapy might be necessary if the nucleic acid effect wanes (though for DNA vectors and genome editing, the aim is one-and-done). Notably, viral vectors like AAV are designed to be extremely nuclease-resistant (protected by capsid, and once in the nucleus, forming circular concatemer structures that are relatively stable). Non-viral approaches are catching up by improving stability and targeting, as evidenced by Altogen’s products that emphasize “minimal toxicity” and “efficiency” which indirectly speaks to overcoming these hurdles.

Altogen’s documentation specifically highlights serum stability (16h), minimal cytotoxicity (meaning their reagent doesn’t induce conditions that might lead to DNA damage or release of DNases from dying cells), and broad tissue delivery which implies it gets the nucleic acid where it needs to go before it degrades.

Conclusion

Nuclease activity and nucleic acid degradation pathways form a gauntlet that exogenous DNA or RNA must survive for successful liver transfection. From the moment a nucleic acid is introduced, it faces immediate attack by extracellular DNases and RNases, and those molecules that enter hepatocytes are threatened by endo/lysosomal enzymes like DNase II and cytosolic surveillance nucleases like TREX1. Without protection, the majority of genetic cargo can be destroyed before reaching its site of action, explaining the historically low efficiency of naked DNA/RNA delivery.

Modern gene delivery systems are explicitly designed to shield nucleic acids from these threats. Lipid nanoparticles and polymer complexes create a protective vehicle that not only facilitates cellular uptake but also masks the cargo from nucleases. As we’ve discussed, stability in serum is a critical metric – Altogen’s liver transfection complexes maintaining integrity for hours in blood demonstrates a huge improvement over naked DNA’s lifespan. Similarly, chemical tweaks to the nucleic acid backbone and bases make it a less appetizing substrate for nucleases, dramatically extending the effective duration of gene silencing for siRNAs or protein production for mRNAs. The success of therapies like inclisiran (a GalNAc-conjugated siRNA for LDL cholesterol control) which requires dosing only every 6 months, attests to the power of these stability enhancements (inclisiran’s siRNA is heavily modified and liver-targeted).

In the intracellular environment, successful transfection goes hand-in-hand with efficient endosomal escape – a DNA that quickly escapes to the cytosol and enters the nucleus can sometimes outrun degradative pathways. For instance, hydrodynamic injection delivers DNA so rapidly into hepatocyte nuclei that substantial expression is achieved before nucleases can intervene. While not applicable clinically, it underscores the concept of beating the clock of degradation.

In summary, by understanding the degradation pathways, scientists have devised multi-layered strategies to preserve delivered genes long enough to function. Every aspect, from molecular modifications to delivery vehicle design, contributes to evading nucleases and prolonging transgene presence. Continued innovations, such as improved endosome-disruptive chemistries and novel nuclease inhibitors, could further boost the efficiency of liver-directed gene therapy. With robust protective measures as exemplified by products from Altogen and others, nucleic acids can survive the hostile journey through the body to reach hepatic cells and achieve the desired therapeutic effect.

Sources: Rapid clearance of naked DNA in blood; lysosomal DNase II barrier; TREX1 cytosolic degradation; Altogen complex stability in serum.

Similar Posts